Drug Insights

Master Loperamide Search on Synapse

26 March 2024
2 min read

Loperamide, an FDA-approved small molecule drug since December 1976, is a puzzling substance that binds to opioid receptors, specifically the mu, kappa, and delta receptors, and acts as an agonist, to reduce the frequency and urgency of bowel movements by slowing down the movement of the intestines. Diarrhea is the main indication of this drug, which is administered to alleviate symptoms associated with this condition. Johnson & Johnson is the originator organization of Loperamide, and the drug has been used widely in clinical practice for decades. Although Loperamide may cause side effects, including constipation and abdominal cramping, it remains an important tool in the treatment of diarrhea. Nonetheless, it is worth noting that Loperamide should not be utilized in cases of fever or bloody or mucus-filled stools as they could indicate more severe underlying conditions. Click on the image below to begin the exploration journey of Loperamide through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Aprocitentan: The Hypertension Drug Once Rejected by J&J Now Secures FDA Approval for Market Release
Hot Spotlight
10 min read
Aprocitentan: The Hypertension Drug Once Rejected by J&J Now Secures FDA Approval for Market Release
26 March 2024
On March 20th, Idorsia, a Swiss pharma, announced FDA approval for their drug TRYVIO™ (aprocitentan) to be used alongside other antihypertensives for treating uncontrolled hypertension in adults.
Read →
Promising Early Results for ACELYRIN's Lonigutamab in Thyroid Eye Disease Studies
Latest Hotspot
3 min read
Promising Early Results for ACELYRIN's Lonigutamab in Thyroid Eye Disease Studies
26 March 2024
ACELYRIN, INC. has revealed encouraging initial data from its Phase 1/2 studies for Lonigutamab. This first-of-its-kind, injectable treatment targeting IGF-1R has shown promising therapeutic effects in patients suffering from Thyroid Eye Disease.
Read →
Entera Bio Reveals Promising Oral GLP-2 Pill Efficacy for Short Gut Syndrome
Latest Hotspot
3 min read
Entera Bio Reveals Promising Oral GLP-2 Pill Efficacy for Short Gut Syndrome
24 March 2024
Entera Bio Unveils Strong Drug Absorption Results for Innovative Oral GLP-2 Hormone Pill Designed for Individuals with Short Gut Condition.
Read →
Unveiling Fexofenadine: How to Search for it on Synapse
Drug Insights
2 min read
Unveiling Fexofenadine: How to Search for it on Synapse
24 March 2024
Approved by the FDA in March 1996, Fexofenadine is a puzzling small molecule drug that works as an H1 receptor antagonist.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.